Free Trial

Mustang Bio (MBIO) Competitors

$0.15
0.00 (0.00%)
(As of 06/12/2024 ET)

MBIO vs. TENX, CYCN, LGVN, ASLN, EFTR, CLVR, GRTX, XBIO, KTTA, and BNOX

Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Tenax Therapeutics (TENX), Cyclerion Therapeutics (CYCN), Longeveron (LGVN), ASLAN Pharmaceuticals (ASLN), eFFECTOR Therapeutics (EFTR), Clever Leaves (CLVR), Galera Therapeutics (GRTX), Xenetic Biosciences (XBIO), Pasithea Therapeutics (KTTA), and Bionomics (BNOX). These companies are all part of the "pharmaceutical preparations" industry.

Mustang Bio vs.

Mustang Bio (NASDAQ:MBIO) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.

Mustang Bio received 29 more outperform votes than Tenax Therapeutics when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 58.58% of users gave Tenax Therapeutics an outperform vote.

CompanyUnderperformOutperform
Mustang BioOutperform Votes
169
64.26%
Underperform Votes
94
35.74%
Tenax TherapeuticsOutperform Votes
140
58.58%
Underperform Votes
99
41.42%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A-$51.60M-$4.40-0.03
Tenax TherapeuticsN/AN/A-$7.71MN/AN/A

9.9% of Mustang Bio shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 2.1% of Mustang Bio shares are held by insiders. Comparatively, 0.3% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mustang Bio has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Mustang Bio currently has a consensus price target of $12.00, indicating a potential upside of 8,091.13%. Tenax Therapeutics has a consensus price target of $480.00, indicating a potential upside of 14,185.71%. Given Tenax Therapeutics' higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Mustang Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mustang Bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tenax Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tenax Therapeutics' return on equity of -89.73% beat Mustang Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Mustang BioN/A -1,243.22% -195.64%
Tenax Therapeutics N/A -89.73%-77.60%

In the previous week, Mustang Bio had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Mustang Bio and 2 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Mustang Bio's score of 0.94 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Mustang Bio Positive
Tenax Therapeutics Very Positive

Summary

Mustang Bio and Tenax Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBIO vs. The Competition

MetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.78M$6.99B$5.14B$8.40B
Dividend YieldN/A2.65%5.28%4.06%
P/E Ratio-0.0312.10139.7515.61
Price / SalesN/A275.072,275.5273.81
Price / CashN/A32.7633.6430.81
Price / Book14.255.654.944.35
Net Income-$51.60M$146.90M$109.47M$215.60M
7 Day Performance-18.57%-1.23%-0.55%-0.05%
1 Month Performance-45.19%1.12%0.71%1.39%
1 Year Performance-98.01%-4.16%3.50%5.26%

Mustang Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TENX
Tenax Therapeutics
2.8137 of 5 stars
$3.54
+2.6%
$480.00
+13,459.3%
-86.9%$6.94MN/A0.005Short Interest ↓
Positive News
CYCN
Cyclerion Therapeutics
0 of 5 stars
$2.54
-0.4%
N/A-47.8%$6.88M$1.62M0.001News Coverage
High Trading Volume
LGVN
Longeveron
2.7116 of 5 stars
$1.08
+3.8%
$12.00
+1,011.1%
-97.6%$6.86M$710,000.00-0.1123Gap Up
ASLN
ASLAN Pharmaceuticals
2.0621 of 5 stars
$0.41
-1.9%
$11.33
+2,649.5%
-89.1%$6.74M$12M-0.1535Gap Up
EFTR
eFFECTOR Therapeutics
2.7637 of 5 stars
$1.27
-3.1%
$24.00
+1,789.8%
-96.2%$5.97M$3.55M-0.1014Short Interest ↓
Positive News
CLVR
Clever Leaves
0 of 5 stars
$3.38
+4.6%
N/A-57.0%$5.92M$17.42M-0.30296Gap Down
GRTX
Galera Therapeutics
0 of 5 stars
$0.11
-0.7%
N/A-96.9%$5.89MN/A-0.117Short Interest ↓
XBIO
Xenetic Biosciences
0.3116 of 5 stars
$3.80
-2.8%
N/A+15.2%$5.85M$2.54M-1.304Short Interest ↑
Gap Down
KTTA
Pasithea Therapeutics
0 of 5 stars
$5.60
-1.6%
N/A-40.9%$5.84M$20,000.000.008
BNOX
Bionomics
2.68 of 5 stars
$0.71
+0.0%
$9.00
+1,167.2%
-69.9%$5.80M$10,000.000.00N/AAnalyst Forecast

Related Companies and Tools

This page (NASDAQ:MBIO) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners